Nanjing Vazyme Biotech Co Ltd (688105) - Cash Flow Conversion Efficiency

Latest as of September 2025: 0.020x

Based on the latest financial reports, Nanjing Vazyme Biotech Co Ltd (688105) has a cash flow conversion efficiency ratio of 0.020x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥75.30 Million ≈ $11.02 Million USD) by net assets (CN¥3.84 Billion ≈ $562.02 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Nanjing Vazyme Biotech Co Ltd - Cash Flow Conversion Efficiency Trend (2017–2024)

This chart illustrates how Nanjing Vazyme Biotech Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read 688105 liabilities breakdown for a breakdown of total debt and financial obligations.

Nanjing Vazyme Biotech Co Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Nanjing Vazyme Biotech Co Ltd ranked by their cash flow conversion efficiency.

Company Cash Flow Conversion Efficiency
Luye Pharma Group Ltd
F:LUP
0.021x
Hnac Technology Co Ltd
SHE:300490
0.023x
Shanghai Hugong Elec(Group)
SHG:603131
0.000x
RITES Limited
NSE:RITES
-0.030x
Taiyuan Heavy Industry Co Ltd
SHG:600169
0.080x
Ramsay Generale De Sante
PA:GDS
0.060x
Johnson Health Tech Co Ltd
TW:1736
-0.003x
Ami Organics Limited
NSE:AMIORG
0.006x

Annual Cash Flow Conversion Efficiency for Nanjing Vazyme Biotech Co Ltd (2017–2024)

The table below shows the annual cash flow conversion efficiency of Nanjing Vazyme Biotech Co Ltd from 2017 to 2024. For the full company profile with market capitalisation and key ratios, see Nanjing Vazyme Biotech Co Ltd stock valuation.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2024-12-31 CN¥3.94 Billion
≈ $577.07 Million
CN¥-9.68 Million
≈ $-1.42 Million
-0.002x -104.99%
2023-12-31 CN¥4.03 Billion
≈ $589.61 Million
CN¥198.40 Million
≈ $29.03 Million
0.049x -69.11%
2022-12-31 CN¥4.61 Billion
≈ $674.90 Million
CN¥735.17 Million
≈ $107.58 Million
0.159x +6.66%
2021-12-31 CN¥4.13 Billion
≈ $603.95 Million
CN¥616.80 Million
≈ $90.26 Million
0.149x -75.22%
2020-12-31 CN¥1.33 Billion
≈ $194.97 Million
CN¥803.55 Million
≈ $117.59 Million
0.603x +693.51%
2019-12-31 CN¥200.02 Million
≈ $29.27 Million
CN¥15.20 Million
≈ $2.22 Million
0.076x +415.63%
2018-12-31 CN¥166.08 Million
≈ $24.30 Million
CN¥-4.00 Million
≈ $-585.21K
-0.024x +5.92%
2017-12-31 CN¥150.82 Million
≈ $22.07 Million
CN¥-3.86 Million
≈ $-564.87K
-0.026x --

About Nanjing Vazyme Biotech Co Ltd

SHG:688105 China Biotechnology
Market Cap
$1.18 Billion
CN¥8.03 Billion CNY
Market Cap Rank
#8461 Global
#2193 in China
Share Price
CN¥20.20
Change (1 day)
+1.25%
52-Week Range
CN¥18.23 - CN¥26.44
All Time High
CN¥119.29
About

Nanjing Vazyme Biotech Co., Ltd offers technology solutions for life science, biomedicine, and in vitro diagnostics. The company offers nucleic acid extraction reagents, including DNA extraction, RNA extraction, microbiome nucleic acid extraction, sample treatment, and high-throughput automated extraction; molecular biology reagents comprising PCR, cloning/mutagenesis, reverse transcription, real… Read more